Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Australian Clinical Research Grants Algernon $600k Tax Credit

Stockhouse Editorial November 16, 2020

Algernon Pharmaceuticals Announces Receipt of Refundable Tax Credit from Australian Clinical Research

GlobeNewswire November 16, 2020

Algernon Pharmaceuticals Provides Update on its Ifenprodil Phase 2 Clinical Trials Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire November 13, 2020

Algernon to Provide Interim Data from COVID-19 Human Study

Stockhouse Editorial November 9, 2020

Algernon Pharmaceuticals Announces Plans to Provide Interim Data from its Ifenprodil Phase 2b/3 COVID-19 Human Study

GlobeNewswire November 9, 2020

Data and Safety Monitoring Board Approve Algernon’s COVID Study

Stockhouse Editorial October 30, 2020

Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

GlobeNewswire October 30, 2020

25% Enrollment in Algernon’s Phase 2 Chronic Cough Study

Stockhouse Editorial October 13, 2020

Algernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

GlobeNewswire October 13, 2020

Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific Advisory Board

GlobeNewswire October 9, 2020

Algernon Reaches 75% Enrollment in Human COVID Study

Stockhouse Editorial October 2, 2020

Algernon Announces 75% Enrollment in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

GlobeNewswire October 2, 2020

Algernon Enrolls 100th Patient in Multinational Study to Treat COVID-19

Stockhouse Editorial September 29, 2020

Algernon Announces Enrollment of 100 Patients in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

GlobeNewswire September 29, 2020

Algernon Announces 50% Enrollment in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

GlobeNewswire September 22, 2020

Algernon Announces Data and Safety Monitoring Board Recommends the Continuation of its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

GlobeNewswire September 16, 2020

Algernon Enrolls 50th Patient in Multinational Study to Treat COVID-19

Stockhouse Editorial September 2, 2020

Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

GlobeNewswire September 2, 2020

The Health & Wellness Business: Thriving in a COVID World

Jonathon Brown August 26, 2020

Algernon Pharmaceuticals Inc., Next Phase Study of Ifenprodil for COVID-19 Treatment, CEO Clip Video

Newsfile August 25, 2020